WEST LAFAYETTE, Ind., Jan. 15, 2019 /PRNewswire/ -- On Target Laboratories, Inc., a privately held biotechnology company that is developing tumor-targeted fluorescent dyes to improve cancer surgery, announced today the appointment of Benjamin Lundgren as Vice President of Marketing and Commercialization. Mr. Lundgren will lead the commercialization and marketing strategies for the company's cancer-illuminating small molecule portfolio, including OTL38, at On Target Laboratories.
"Ben has more than 18 years of experience leading marketing teams and executing on commercialization plans for billion-dollar platforms," said Martin Low, CEO of On Target Laboratories. "He will play a fundamental role in strategy and positioning at On Target Laboratories as we advance our pipeline of cancer-highlighting probes and reach our critical clinical milestones."
Mr. Lundgren most recently served as Senior Director, Global Strategic Marketing at Ethicon, part of Johnson & Johnson Medical Devices Companies, where he led development and implementation of the marketing strategy for the minimally-invasive stapling platform. Prior to his four-year tenure at Ethicon, Mr. Lundgren held positions at the Janssen Pharmaceutical Companies of Johnson & Johnson where he successfully developed and led commercialization strategy efforts. He has also held positions at Bain & Company. Mr. Lundgren received his MBA from the Wharton School.
"I was attracted to On Target Laboratories because of the disruptive nature of their technology, focus on patient outcomes and strong executive leadership team," said Mr. Lundgren. "On Target Laboratories is a pioneer in intraoperative cancer visualization molecules and I look forward to joining the On Target team in their mission to improve the welfare of cancer patients worldwide."
About On Target Laboratories, Inc.
On Target Laboratories Inc., is in the business of discovering, developing and commercializing small molecules that, when conjugated with fluorescent dyes, target and illuminate specific cancerous cells and other diseased tissue. These conjugates can be used by doctors, including surgeons, worldwide to better diagnose and treat a wide range of diseases from cancer to inflammation-related disorders. OTL38 is currently under clinical development for use in ovarian and lung cancer surgery. For more information visit www.ontargetlaboratories.com.
Travis Kruse, Ph.D.
Russo Partners LLC
Purdue Research Foundation:
SOURCE On Target Laboratories